Budget impact analysis of antiepileptic drugs for lennox-gastaut syndrome

Journal of Managed Care Pharmacy

Volumn 20, Issue 4, 2014, Pages 400-406

  Skornicki, Michelle ^a   Clements, Karen M ^a   O'Sullivan, Amy K ^a  

^a OPTUM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CLOBAZAM; LAMOTRIGINE; RUFINAMIDE; TOPIRAMATE; VALPROIC ACID; BENZODIAZEPINE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BUDGET IMPACT ANALYSIS; CHILD; CLINICAL STUDY; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; DRUG EFFICACY; DRUG WITHDRAWAL; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; LENNOX GASTAUT SYNDROME; MAJOR CLINICAL STUDY; MEDICAL CARE; MIDDLE AGED; PRESCHOOL CHILD; SCHOOL CHILD; TREATMENT OUTCOME; YOUNG ADULT; BUDGET; ECONOMICS; FACTUAL DATABASE; PATHOPHYSIOLOGY; PUBLICATION; RETROSPECTIVE STUDY; UNITED STATES;

ADOLESCENT; ADULT; ANTICONVULSANTS; BENZODIAZEPINES; BUDGETS; CHILD; CHILD, PRESCHOOL; COST SAVINGS; DATABASES, FACTUAL; FORMULARIES AS TOPIC; HUMANS; LENNOX GASTAUT SYNDROME; MANAGED CARE PROGRAMS; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84896972874     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2014.20.4.400     Document Type: Article

References (27)

1. Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol. 2009;8(1):82-93.
2. Camfield PR. Definition and natural history of Lennox-Gastaut syndrome. Epilepsia. 2011;52(Suppl 5):S3-S9.
3. Arzimanoglou A, Resnick T. All children who experience epileptic falls do not necessarily have Lennox-Gastaut syndrome... but many do. Epileptic Disord. 2011;13(Suppl 1):S3-S13.
4. Camfield C, Camfield P. Twenty years after childhood-onset symptomatic generalized epilepsy the social outcome is usually dependency or death: a population-based study. Dev Med Child Neurol. 2008;50(11):859-63.
5. Autry AR, Trevathan E, Van Naarden Braun K, Yeargin-Allsopp M. Increased risk of death among children with Lennox-Gastaut syndrome and infantile spasms. J Child Neurol. 2010;25(4):441-47.
6. Kerr M, Kluger G, Philip S. Evolution and management of Lennox-Gastaut syndrome through adolescence and into adulthood: are seizures always the primary issue? Epileptic Disord. 2011;13(Suppl 1):S15-S26.
7. Gallop K, Wild D, Nixon A, Verdian L, Cramer JA. Impact of Lennox-Gastaut Syndrome (LGS) on health-related quality of life (HRQL) of patients and caregivers: literature review. Seizure. 2009;18(8):554-58.
8. Camfield PR, Gibson PA, Douglass LM. Strategies for transitioning to adult care for youth with Lennox-Gastaut syndrome and related disorders. Epilepsia. 2011;52(Suppl 5):S21-S27.
9. Beghi E, Frigeni B, Beghi M, De Compadri P, Garattini L. A review of the costs of managing childhood epilepsy. PharmacoEconomics. 2005;23(1):27-45.
10. Berry JG, Poduri A, Bonkowsky JL, et al. Trends in resource utilization by children with neurological impairment in the United States inpatient health care system: a repeat cross-sectional study. PLoS Med. 2012;9(1):e1001158.
11. Standridge SM, Horn PS. Variations in hospitalization outcomes in children admitted with seizures between 2003 and 2006. J Child Neurol. 2012;27(7):898-906.
12. Yoon D, Frick KD, Carr DA, Austin JK. Economic impact of epilepsy in the United States. Epilepsia. 2009;50(10):2186-91.
13. Begley CE, Famulari M, Annegers JF, et al. The cost of epilepsy in the United States: an estimate from population-based clinical and survey data. Epilepsia. 2000;41(3):342-51.
14. Cramer JA, Sapin C, François C. Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome. Acta Neurol Scand. 2013;128(2):91-99.
15. Benedict A, Verdian L, Maclaine G. The cost effectiveness of rufinamide in the treatment of Lennox-Gastaut syndrome in the UK. Pharmacoeconomics. 2010;28(3):185-99.
16. Verdian L, Yi Y. Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom. Seizure. 2010;19(1):1-11.
17. Ng YT, Conry JA, Drummond R, et al. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology. 2011;77(15):1473-81.
18. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology. 2008;70(21):1950-58.
19. Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A doubleblind, randomized trial of topiramate in Lennox-Gastaut syndrome. Topiramate YL Study Group. Neurology. 1999;52(9):1882-87.
20. Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N Engl J Med. 1997;337(25):1807-12.
21. Kobau R, Zahran H, Thurman DJ, et al. Epilepsy surveillance among adults-9 States, Behavioral Risk Factor Surveillance System, 2005. MMWR Surveill Summ. 2008;57(6):1-20.
22. Clements KM, Skornicki M, O'Sullivan AK. Cost-effectiveness analysis of antiepileptic drugs in the treatment of Lennox-Gastaut syndrome. Epilepsy Behav. 2013;29(1):184-89.
23. Ng YT, Conry J, Paolicchi J, et al. Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: interim results of an open-label extension study. Epilepsy Behav. 2012;25(4):687-94.
24. Kluger G, Glauser T, Krauss G, Seeruthun R, Perdomo C, Arroyo S. Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, openlabel extension study. Acta Neurol Scand. 2010;122(3):202-08.
25. Glauser TA, Levisohn PM, Ritter F, Sachdeo RC, et al. Topiramate in Lennox-Gastaut Syndrome: open-label treatment of patients completing a randomized controlled trial. Epilepsia. 2000;41(Suppl 1):S86-S90.
26. PDR Network. Red Book 2010: Pharmacy's Fundamental Reference. Montvale, NJ: Physicians' Desk Reference Incorporated, 2010.
27. Swindle JP, Song R, Liu F, et al. Economic burden of Lennox-Gastaut Syndrome [abstract]. Value Health. 2012;15(4):A143.